Polyphor achieves ahead of schedule first milestone from Wellcome Trust for the development of novel antibiotics against Gram-negative multidrug - resistant pathogens(PresseBox) (Allschwil, )
Lead candidates have shown excellent activity in vitro and in vivo against a wide panel of Gram-negative pathogens including multidrug-resistant strains. Activity was also shown against bacteria resistant to colistin, a drug often used as a "last resort" antibiotic. In addition, the rate of resistance development observed is very low compared to standard antibiotics.
The World Health Organization considers antibiotic resistance as one of the biggest threats to global health today. If nothing is done, the death toll could increase to 10 millions of people every year by 2050, potentially exceeding the annual number of deaths from cancer (Review on Antimicrobial Resistance, Final Report, May 2016). A new class of antibiotics will significantly increase the chances to overcome this serious global health problem.
Daniel Obrecht, CSO of Polyphor, said: "Reaching this milestone in our collaboration with the Wellcome Trust is a major step in our joint efforts to develop alternative treatments for serious and life-threatening infections. This milestone is yet another validation of our breakthrough antibiotic research which already resulted in Murepavadin, a precision antibiotic for Pseudomonas aeruginosa, now entering Phase III studies. We are grateful that the Wellcome Trust supports our program to advance drug candidates to the clinic expeditiously."
About the Wellcome Trust
The Wellcome Trust exists to improve health for everyone by helping great ideas to thrive. It is a global charitable foundation, both politically and financially independent. The Wellcome Trust support scientists and researchers, take on big problems, fuel imaginations and spark debate.